Recommendations for HER2 testing in the UK

Ellis, Ian O. and Dowsett, M. and Bartlett, J. and Walker, Rosemary A. and Cooke, T. and Gullick, William J. and Gusterson, B. and Mallon, E. and Lee, P. Barrett (2000) Recommendations for HER2 testing in the UK. Journal of Clinical Pathology, 53 (12). pp. 890-892. ISSN 0021-9746. (The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided)

The full text of this publication is not available from this repository. (Contact us about this Publication)
Official URL


Determining the HER2 status of breast carcinomas is a prerequisite for the use of the monoclonal antibody trastuzumab (Herceptin(R)), which has recently been licensed for the treatment of metastatic disease. This necessitates a test based on archival material. The preferred analyses are immunohistochemistry with fluorescent in situ hybridisation (FISH) as a follow up test for ambiguous results. Guidelines have been developed for standardised, well controlled procedures for the provision of reliable results. A group of three reference laboratories has been established to provide advice, quality assurance, and materials, where needed.

Item Type: Article
Uncontrolled keywords: HER2 • breast cancer • Herceptin
Subjects: R Medicine > RB Pathology
R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Divisions: Faculties > Science Technology and Medical Studies > School of Biosciences
Depositing User: O.O. Odanye
Date Deposited: 19 May 2009 00:59
Last Modified: 25 Jun 2014 10:31
Resource URI: (The current URI for this page, for reference purposes)
  • Depositors only (login required):